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Objective: There is remarkable controversy over the processes driving abdominal aneurysm growth. The inherent
limitations of animal and human studies hamper elucidation of the key inflammatory and proteolytic processes. Human
data are largely derived from surgical specimens that typically reflect the final stages of the disease process and thus do not
allow distinction between primary and secondary processes. Clear epidemiologic and genetic associations between
abdominal aortic aneurysm (AAA) and popliteal artery aneurysms (PAA) suggest that that these two pathologies share
common grounds. On this basis, we reasoned that information of corresponding and discordant processes in these
aneurysms might provide critical clues on the processes that are crucial for aneurysm progression.
Methods: Messenger RNA (semi-quantitative real-time polymerase chain reaction) and protein analysis (enzyme-linked
immunosorbent assay, multiplex, Western blotting), and histology were performed on aneurysm wall samples obtained
during elective PAA and AAA repair. Nonaneurysmal aorta tissue from organ donors was included as reference.
Results: Messenger RNA and protein analysis showed that PAA and AAA are both characterized by a marked activation
of nuclear factor-B (NF-B) and activator protein-1 (AP-1) proinflammatory transcription factors, and hyperexpression
of interleukin (IL)-6 and IL-8. Discordant findings were found for other inflammatory markers such as interferon-,
interferon-inducible protein 10, tumor necrosis factor-, monocyte chemotactic protein-1, and macrophage inflamma-
tory protein 1 and , which were all lower in PAA. On the cellular level, both pathologies exhibited profuse infiltration
of macrophages, neutrophils, and T-helper cells. Results for B cells, plasma cells, and cytotoxic T cells were discordant, with
minimal infiltration of these cell types in PAA. Evaluation of protease expression and activation showed that both conditions
are dominated by increased matrix metalloproteinase 8 and 9, and cathepsin K, L and S expression and activation.
Conclusion:This explorative study characterizes degenerative aneurysmal disease general inflammatory conditions that are
dominated by profound activation of the NF-B and AP-1 pathways, hyperexpression of IL-6 and IL-8, and neutrophil
involvement. Discordant findings for interferon , cytotoxic T cells, B cells, and plasma cells challenge a critical role for
these factors in the process of aneurysm growth. Pharmaceutic strategies targeting the common components in AAA and
PAA may prove effective for the stabilization of AAA. (J Vasc Surg 2010;51:1479-87.)
Clinical Relevance: An understanding of the processes driving aneurysm growth is critical for the development of new
therapeutic strategies. Studies in animals and those using human material have helped to identify a variety of molecular
candidates for intervention. Yet, interpretation of the data is complicated by the limited validity of animal models and
because human tissue is generally obtained during surgical abdominal aortic aneurysm repair and thus represents the final
stages of the disease. Strong genetic and epidemiologic associations between abdominal aortic aneurysm and popliteal
aneurysms suggest that these aneurysms share a common ground. We therefore reasoned that information on parallel and
incongruent pathways in these aneurysms may provide critical information on the key processes driving aneurysmal
growth. Results of this study help to identify pathways that are essential to aneurysm growth.From the Department of Vascular Surgery, Leiden University Medical
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doi:10.1016/j.jvs.2010.01.057Abdominal aortic aneurysm (AAA) is a common dilating
disorder of the aorta and a major cause of death due to
rupture.1-3 Despite consensus that AAA is best described as a
chronic inflammatory condition with an accompanying pro-
teolytic imbalance, the exact nature of the inflammatory cas-
cades and the proteases driving aneurysmal growth remain
unresolved. For example, although AAA was initially desig-
nated by Schonbeck et al4 as a T-helper (Th)-2-type inflam-
matory disease, later studies suggest that AAA is better char-
acterized as a Th1-dominated disease,5 or alternatively, as a
general proinflammatory disease.6 With respect to the pro-
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gelatinase matrix metalloproteinase (MMP) 9. Yet, despite
ample evidence in animal models for a crucial involvement of
MMP9 in AAA formation and growth of the disease, the
pivotal role of MMP9 in driving human AAA growth is
debated,7 and additional proteases such as MMP8 and the
cysteine proteases cathepsin K, L, and S have now also been
brought forward.8
Interpretation of the available data is further compli-
cated because most data are based on surgical specimens or
on animal models of the disease. Surgical specimens gener-
ally represent the final stages of the disease process, making
it difficult to discriminate between the primary and second-
ary events in the disease process.9,10 Similarly, although
animal models may provide valuable clues to the disease
process, their relevance for AAA in general remains to be
established.9
There are remarkable associations between AAA and
popliteal artery aneurysms (PAA), the by far most common
forms of peripheral aneurysms.11,12 This is not only re-
flected by the fact that not only are about 40% to 50% of
patients with a PAA also diagnosed with an AAA13,14 but
also by the aggregation of AAA and PAA in relatives of
patients with these aneurysms as well as by functional
analysis showing that the popliteal artery bears striking
similarities to an elastic artery like the aorta.15 These obser-
vations suggest that AAA and PAA belong to a similar
family of aneurysms, the so-called degenerative aneu-
rysms,16 rather than aneurysms with a monogenetic origin
such as aneurysms associated with Marfan syndrome or
Ehlers-Danlos syndrome, which are respectively related to
dysregulated transforming growth factor- signalling17 or
defective collagen III synthesis.18
We thus reasoned that identification of common factors
in the two conditions may provide clues on the nature of
the inflammatory and proteolytic pathways causatively in-
volved in aneurysm growth and constitutes a first important
step to identify potential therapeutic targets for the phar-
maceutical stabilization of AAA.
Because data from a methodic comparison of AAA and
PAA are missing, we performed an explorative systematic
and comprehensive analysis of inflammatory and proteo-
lytic pathways activated in AAA and PAA tissue to identify
corresponding and discordant processes in these two re-
lated pathologies. This information may identify the pro-
cesses that are actually driving AAA and PAA growth as well
as the bystander processes that are part of the persistent
inflammatory response.
MATERIALS AND METHODS
Sample collection and handling was performed in accor-
dance with the guidelines of the Medical and Ethical Com-
mittee in Leiden, Netherlands and the code of conduct of the
Dutch Federation of Biomedical Scientific Societies (http://
www.federa.org/?s1&m78&p&v4).
Tissue samples. All aneurysm samples were obtained
during elective aneurysm repair. Reference samples (non-
aneurysmal abdominal aortic wall samples) were obtainedfrom the Vascular Tissue Bank at the Department of Vas-
cular Surgery, Leiden, The Netherlands.
All samples were obtained after consent of the patients.
None of the patients had a history of diabetes or chronic
inflammatory disease. AAA samples (anterior lateral aneu-
rysm wall) were obtained from 17 patients (14 men, 3
women) with an AAA 5.5 cm undergoing elective open
repair (AAA group). Patients were a mean age of 72.4 
6.2 years (mean sd), and the mean AAA diameter was 6.7
 1.1 cm. PAA samples were from 12 patients (11 men, 1
woman) with PAA 2.0 cm16 undergoing elective repair.
These patients were aged 69.6  12.1 years.
For comparison of the AAA and PAA wall with the
normal aortic wall (nonaneurysmal control), we used non-
aneurysmal aortic wall patches obtained during clinical
organ transplantation. The grafts were derived from 11
kidney donors (7 men, 4 women) with fatal brain injury
caused by a major head trauma or subarachnoidal bleeding.
Only patches displaying advanced atherosclerosis with ad-
vanced atherosclerotic lesions, equalling the characteristics
of grade IV to VI lesions according to the Stary classifica-
tion,19 were selected. The mean age of the control group
was 55.6 10.2 years, with an aortic diameter of2.0 cm.
All control samples were obtained at the level of the renal
artery and during a laparotomy, that is, from comparable
region and during a similar procedure as the AAA samples.
Tissue procurement. Any adhering thrombus was
carefully removed and the vessel walls were halved length-
wise. One half was immediately snap frozen in liquid nitro-
gen and stored at 80°C for messenger RNA (mRNA)
analysis by real-time polymerase chain reaction (RT-PCR)
and protein analysis using Western blot and enzyme-linked
immunosorbent assay (ELISA). The other half was fixed in
formaldehyde for 24 hours, decalcified in Kristensen solu-
tion for 120 hours, and embedded in paraffin for histologic
analysis.
Real-time PCR. Tissue samples were pulverized in
liquid nitrogen, RNA was isolated, and semi-quantitative
RT LightCycler PCR (Applied Biosystems, Nieuwerkerk
a/d IJssel, The Netherlands) was carried out (TaqMan
method) as detailed in previous publications.20
Total RNA extraction was performed using RNAzol
(Campro Scientific, Veenendaal, The Netherlands) and
glass beads according to the manufacturer’s instructions.
Copy DNA was prepared (Kit #A3500; Promega, Leiden,
The Netherlands), and quantitative RT-PCR analysis was
performed for human interleukin (IL)-1, IL-1, IL-2, IL-6,
IL-8, tumor necrosis factor (TNF), monocyte chemotactic
protein (MCP)-1, macrophage inflammatory protein (MIP)-
1, macrophage inhibition factor, transforming growth factor
(TGF)-, CD4, T-Bet, GATA-3, IL-4, IL-10, IL-13, inter-
feron , CD8, perforin, granzyme A, B-lymphocyte-induced
maturation protein 1 (BLIMP-1), MAD4, immunoglobulin
linker protein, immunoglobulin heavy chain, MMP-25,
CD 337, tryptase, MMP2, MMP3, MMP9, MMP13, tis-
sue inhibitor of metalloproteinases (TIMP)-1, TIMP-2,
TIMP-3, cathepsin K, cathepsin L, cathepsin S, cystatin C,
urokinase plasminogen activator (uPA), and plasminogen
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(Applied Biosystems) using established primer/probe sets
(Assays on Demand; Applied Biosystems) and Mastermix
(Eurogentec, Seraing, Belgium). Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) expression was used as a
reference and for normalization.
Tissue homogenization. Snap frozen samples were
crushed in liquid nitrogen and mixed with lysis buffer (10
mM Tris, pH 7.0; 0.1 mM CaCl2, 0.1 M NaCl, 0.25%
(v/v) Triton X-100) for protein-based assays. After centrif-
ugation at 4°C for 15 minutes at 13,000 rpm, the superna-
tants were collected, and protein contents were measured
(Pierce, Rockford, Ill) before storage at 80°C until use.
Multiplex assay, and IL-6, IL-8 and MCP-1 ELISAs.
Concentrations of vessel wall cytokines were measured in
the homogenates by the BioPlex panel (Bio-Rad Laborato-
ries BV, Veenendaal, The Netherlands) for IL-1, IL-1,
IL-13, TNF-, interferon-, IP-10, MIP-1, MIP-1, and
granulocyte colony-stimulating factor (G-CSF), or by sep-
arate ELISAs (PeliKane compact kit; Sanquin, Amsterdam,
The Netherlands) for IL-6 and IL-8, and the Quantikine
kit (R&D Systems, Abingdon, UK) for MCP-1. We previ-
ously concluded that wall of IL-2, IL-4, IL-5, IL-7, IL-10,
IL-12, IL-17A, and granulocyte macrophage colony-
stimulating factor (GM-CSF) in the AAA wall are all at or
below the detection threshold of the multiplex assay.
Hence, these cytokines were not included in the analysis.
Western blotting. Quantifiable Western blots were
performed following detailed protocols described by Klee-
mann et al.21 All assays were performed on the tissue
homogenates using antibodies specific for the human forms
of p65-NF-	B (active form of p65-NF-	B; Chemicon,
#MAB3026, Chemicon Europe Ltd, Chandlers Ford,
UK), p65-NF-	B (nonactive form; sc-8008; Santa Cruz,
Heerhugowaard, The Netherlands), c-Jun (sc-45), phos-
phor (Ser73)-c-Jun (sc-7981), CCAAAT/enhancer-
binding protein (C/EBP)- (sc-9315), C/EBP-
(sc-150), C/EBP-
 (sc-636), MMP2 (PC-158, the Bind-
ingsite, Birmingham, UK), MMP8 (MAB3316, Chemi-
con, Chemicon Europe, Ltd, Chandlers Ford, UK),
MMP9 (TNO-BEA-21), cathepsin K (IM55L, Calbio-
chem, Breda, The Netherlands), cathepsin L (AF952,
R&D systems, Abingdon, UK), cathepsin S (sc-6505,
Santa Cruz), and -actin (sc-1615, Santa Cruz) for normal-
ization. All protease antibodies were specifically chosen to
effectively detect both the pro and activated forms of the
proteases.8
All secondary antibodies were obtained from Santa Cruz
Biotechnology. Immunoblots were visualized using Super
Signal West Dura Extended Duration Substrate (Perbio Sci-
ence, Etten-Leur, The Netherlands) and a luminescent image
workstation (UVP, Cambridge, UK). Immunoblots were
quantified using LabWorks 4.6 software (Bio-Rad, Hercules,
Calif).
Immunohistochemistry. Immunohistochemistry was
performed using deparaffinized, ethanol rehydrated tissue
4-m-thick cross-sections as reported previously.22 Sec-
tions were incubated overnight with polyclonal antibodiesspecifically for human myeloperoxidase (DAKO, Heverlee,
Belgium), CD4 (clone 1F6, DAKO), CD8 (clone 4B11,
Novocastra, Valkenswaard, the Netherlands), CD20 (clone
L26, DAKO), CD68 (clone KP6, DAKO), and CD138
(clone B-B4, Serotec, Oxford, UK). Conjugated biotinyl-
ated antigoat or rabbit anti-immunoglobin (Ig) G were
used as secondary antibodies. Sections were developed with
Nova Red (Vector Laboratories, Burlingame, Calif) and
counterstained with Mayer hematoxylin, allowing morpho-
logic analysis. Specificity of the antibody staining was con-
firmed by omitting the primary antibody. Specimens were
quantified by counting the number of cells per unit area for at
least 20 fields at original magnification400.
Statistical analysis. Messenger RNA and protein ex-
pressions, results of the Western blots and immunohisto-
chemistry were analyzed by Wilcoxon-Mann-Whitney U
test to compare the different groups. Statistical significance
was accepted at P  .05. Most of the data in this study
reflect coherent data that fits in the theoretic inflammatory
frame works. As such, noncorrected data are provided,23
yet a Bonferroni correction should be considered when
interpreting noncoherent data. All analyses were performed
using SPSS 16.0 software (SPSS Inc, Chicago, Ill).
RESULTS
Patient characteristics are reported in Table I.
Cellular composition and cellular markers in AAA
and PAAwalls. We first performed a histologic evaluation
of infiltrating leucocytes in AAA, PAA, and nonaneurysmal
control aorta. Results of these analyses are shown in Fig 1.
AAA and PAA tissues were characterized by profuse and
diffuse infiltration of monocytes (CD68), neutrophils
(MPO), and T-helper cells (CD4). Findings for B-cells
(CD20), plasma cells (CD138), and cytotoxic T-cells
(CD8) content, on the other hand, were clearly discordant
between PAA and AAA, with CD20, CD138 and
CD8 abundance in AAA but with very limited presence in
PAA.
The findings for the reduced B-cell, plasma cell, and
Table I. Patient characteristics
Variable AAA PAA Control aorta
Evaluable patients, No. 15 12 11
Age, mean  SD, y 74.8  6.2 69.6  12.1 55.6  10.2
Diameter, mean  SD,
cm 6.7  1.1 3.35  1.36 2.0
Female sex, No. 1 1 4
Aneurysm elsewhere,
No. 1 4 0
Current smoker, No. 6 4 4
Statin use, No. 1 3 0
Antihypertensives, No. 8 5 0
Antiplatelet therapy,
No. 10 9 0
AAA, Abdominal aortic aneurysm; PAA, popliteal artery aneurysm; SD,
standard deviation.cytotoxic T-cell content in PAA were in accordance with a
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toxic T-cell markers in PAA (Table II). In line with the
cellular observations, no difference was found for the ex-
pression of monocyte/macrophage, neutrophil and the
T-helper cell markers in AAA and PAA (Table II).
Analysis of inflammatory molecular factors in AAA
and PAA walls. Comparison of the AAA and PAA inflam-
matory fingerprint on the mRNA level (semi-quantitative
RT-PCR) and protein level shows that PAA and AAA are
characterized by particularly prominent IL-6 and IL-8 ex-
pression (Table II, Fig 2), although the increase in IL-6
levels was less prominent in PAA than in AAA (P  .038;
Fig 2). Findings for the other proinflammatory factors such
as TNF-, interferon , and IP-10, as well as MCP-1,
MIP, and MIP-, were clearly discordant between AAA
and PAA (P  .008, Table III).
The congruent IL-8 hyperexpression in AAA and PAA
prompted us to quantify the baseline levels of the general
proinflammatory transcription factors NF-	B, AP-1, and
C/EBP. Similar baseline but clearly increased NF-	B and
AP-1 activation (active confirmation [NF-	B] and phos-
phor-c-jun [AP-1]) show that AAA and PAA are both
associated with a hyperactivation of these systems6,24 (Fig
3). Abundance of the C/EBP isoforms , , and 
 was less
outspoken in PAA (P  .021; Fig 3).
Protease profiles in AAA and PAA. MMP2, 8, and
9, and cathepsin K, L, and S have been implicated as the
primary proteolytic culprits in AAA.8 Evaluation of these
proteases on the messenger and protein level showed a
similar profile in PAA (Table II), although a trend towards
lower expression of the cysteine proteases was observed in
PAA. Activation of these proteases was assessed by quanti-
fication of the activated forms in Western blot analysis.8
With the sole exception of reduced cathepsin K and in-
creased MMP2 activation in PAA (P  .005), similar
activation profiles were found in AAA and PAA (Fig 4).
DISCUSSION
The primary processes driving progression of AAA and
PAA, the so-called degenerative aneurysms, are still unre-
solved. To obtain clues on the factors that are generic for
aneurysm growth, we performed a systematic comparison
of inflammatory and proteolytic processes in AAA and
PAA. Our findings demonstrate that both pathologies
share a general proinflammatory profile that is dominated
by IL-8 and IL-6 hyperexpression. Abundance of neutro-
phils, macrophages, and T-helper cell infiltration, as well as
ample expression of MMP and cysteine proteases, are clear
features of the diseases. Distinct differences were found for
the presence of cytotoxic T cells, B cells, and plasma cells, as
well as for their associated markers, suggesting that the
abundance of these cells in AAA is not generic to the
progression of degenerative aneurysms.
The pathology of AAA is complex and poorly under-
stood,1 and very limited information is available for PAA.
Remarkable controversy exists on the inflammatory cas-
cades driving AAA aneurysm growth.25 In a first evaluation,Fig 1. A, The cellular composition of abdominal aortic aneurysm
(AAA; black), popliteal artery aneurysm (PAA; gray), and control
aorta (white) tissue by immunohistochemical analysis is shown in
graph form. The amount of cells/mm2 in AAA and PAA tissues, and
control aorta is shown after staining with antibodies specifically de-
tectingmonocytes andmacrophages (CD68), neutrophils (myeloper-
oxidase [MPO]), T helper cells (CD4), cytotoxic T cells (CD8),
B-lymphocytes (CD20), and plasma cells (CD138). There was no
significant difference between AAA and PAA with respect to CD68
(P  .672), MPO (P  .075), and CD4 (P  .181). Significant
differenceswere found in theCD8 (P .026),CD20 (P .026), and
CD138 (P  .001) content. A statistical difference (P  .05)
between two groups is indicated by a horizontal bar above the bars.
Representative examples of the staining are shown in section B.Schonbeck et al4 reported dominance of the T-helper (Th)
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minimal expression of the Th1-associated cytokine interfer-
on- in AAA.4 On this basis, the authors concluded that
AAA is best described as a Th2-driven disease. Contrary to
these findings, Xiong et al26 (mouse model) and Galle et al5
(human AAA) reported Th1 polarization in AAA. Because
of these apparent contrasting findings, we performed a
comprehensive evaluation of the inflammatory fingerprint
Table II. Log relative expression of markers of inflammat
aneurysm, and nonaneurysmal aortic controla
Variable
PAA AAA
Median (IQR) Median (IQR
Cytokines
IL-1 3.12 (3.32 to 2.81) 2.49 (3.02 to
IL-1 1.40 (2.03 to 1.31) 0.80 (1.17 to
IL-2 3.15 (4.83 to 2.91) 2.92 (3.25 to
IL-6 0.76 (0.84 to 0.73) 0.77 (1.07 to
IL-8 0.56 (1.28 to 0.14) 0.24 (0.84 to
TNF- 1.95 (2.72 to 1.74) 2.43 (2.65 to
MCP-1 0.11 (ND to 0.64) 0.54 (0.10 to 0.
MIP-1 0.71 (0.84 to 0.72) 0.40 (ND to 0
MIF 0.49 (0.32 to 0.59) 0.56 (0.41 to 0
TGF- 0.18 (0.49 to 0.12) 0.30 (0.04 to 0
T-helper cells
CD4 2.75 (2.89 to 2.12) 2.38 (2.74 to
T-Bet 2.67 (3.44 to 2.29) 2.64 (4.96 to
GATA-3 3.04 (3.38 to 2.92) 2.04 (2.64 to
IL-4 ND 3.59 (4.11 to
IL-10 2.09 (2.50 to 1.92) 1.74 (2.22 to
IL-13 ND 3.29 (4.88 to
Interferon- 4.97 (ND to 2.92) 2.71 (3.05 to
Cytotoxic T cell
CD8 2.81 (3.12 to 2.10) 1.49 (1.75 to
Perforin 2.85 (3.31 to 2.72) 2.25 (2.76 to
Granzyme A 1.67 (1.92 to 1.41) 0.83 (1.13 to
B/Plasma cell
BLIMP-1 2.25 (2.82 to 2.04) 1.39 (2.05 to
MAD4 1.45 (1.63 to 1.31) 1.05 (1.49 to
Ig linker protein 0.40 (0.92 to 0.44) 0.26 (0.02 to
Ig heavy chain 0.17 (0.44 to 0.74) 1.76 (1.29 to 2
Neutrophil
MMP25 1.59 (1.91 to 0.92) 1.80 (2.01 to
NK cell
CD337 3.35 (3.79 to 2.77) 2.22 (2.75 to
Proteases
MMP2 1.02 (1.35 to 0.96) 2.64 (3.31 to
MMP3 2.21 (2.87 to 1.35) 2.42 (3.17 to
MMP9 1.06 (1.26 to 0.82) 1.27 (1.56 to
MMP13 2.11 (2.36 to 1.25) 3.15 (3.51 to
Cathepsin K 1.79 (2.71 to 1.69) 1.83 (2.20 to
Cathepsin L 0.67 (0.22 to 0.81) 0.18 (0.16 to
Cathepsin S 0.52 (0.87 to 0.48) 0.71 (0.84 to
TIMP-1 0.74 (0.01 to 0.87) 0.63 (0.22 to 1
TIMP-2 1.50 (1.72 to 1.36) 1.37 (1.54 to
TIMP-3 0.54 (0.81 to 0.35) 0.54 (0.90 to
Cystatin C 0.72 (0.32 to 0.91) 0.93 (0.69 to 1.
BLIMP-1, B-lymphocyte-induced maturation protein 1; Ig, immunoglob
protein;MIF,macrophage inhibition factor;MIP,macrophage inflammatory
TGF, transforming growth factor; TIMP, tissue inhibitor of metalloprotein
aExpression normalized on basis of glyceraldehyde-3-phosphate dehydroge
control (final column) responses.
bSignificant difference between PAA and AAA.of AAA and concluded that AAA is best described as ageneral proinflammatory condition with IL-6 and IL-8
hyperexpression and dominance of IL-6– and IL-8–related
responses.6
The persistent inflammatory state in AAA is held re-
sponsible for a proteolytic imbalance that underlies the
excess matrix degradation in the disease. With respect to
the proteases involved, attention has been primarily fo-
cussed on the gelatinases MMP2 and MMP9.27,28 Yet, it
esponses in abdominal aortic aneurysm, popliteal artery
P value Aortic control P value
(PAA vs AAA) Median (IQR) (PAA vs control)
0) .065 ND .071
3) .007b 1.91 (2.74 to 1.35) .270
4) .135 4.86 (ND to 3.60) .091
5) .604 2.19 (2.81 to 1.84) .00013
.348 1.53 (2.61 to 0.86) .085
2) .452 2.81 (3.80 to 1.99) .188
.26 0.11 (0.41 to 0.47) .758
.008b 1.05 (1.58 to 0.44) .230
.222 0.28 (0.20 to 0.37) .246
.001b 0.14 (0.05 to 0.34) .069
6) .99 3.46 (4.22 to 2.12) .328
1) .72 4.01 (ND to 3.25) .069
6) .001b 3.13 (ND to 2.35) .930
8) .010b 3.83 (4.62 to 3.46) .126
5) .106 1.89 (2.28 to 1.35) .525
7) .166 ND .375
3) .008b 5.52 (ND to 3.04) .536
6) .001b 2.91 (4.30 to 1.89) .596
3) .034b 3.38 (4.07 to 2.88) .230
0) .003b 1.96 (2.41 to 1.04) .179
5) .023b 2.92 (3.47 to 2.48) .081
3) .044b 1.41 (1.56 to 1.05) .808
3) .001b 1.21 (1.70 to 0.73) .122
.001b 0.18 (1.18 to 0.56) .536
2) .757 2.94 (3.52 to 2.73) .027
9) .006b 4.16 (4.99 to 3.12) .180
3) .001b 2.55 (3.09 to 1.60) .015
5) .349 3.38 (4.53 to 2.61) .027
7) .288 2.54 (3.34 to 1.24) .011
4) .018b 3.46 (3.66 to 2.66) .043
7) .376 2.30 (2.95 to 1.87) .375
.619 0.14 (0.62 to 0.55) .020
0) .619 1.19 (2.13 to 0.32) .211
.418 0.25 (0.03 to 0.85) .536
3) .178 1.78 (2.03 to 1.33) .216
.973 0.45 (0.62 to 0.17) .301
.087 0.87 (0.75 to 1.01) .270
L, interleukin; IQR, interquartile range; MCP-1, monocyte chemotactic
in;MMP,matrix metalloproteinase;NK, natural killer;ND, not detectable;
F, tumor necrosis factor.
P value is for the comparison of PAA vs AAA (middle column) or PAA vsory r
)
1.8
0.5
2.3
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that it is thus unlikely that these proteases are directly
responsible for the weakening of the aortic wall. As such, it
is very likely that other proteases contribute to the weaken-
Fig 3. Concentrations of inflammatory transcription factors are
characteristic for abdominal aortic aneurysm (AAA) and popliteal
artery aneurysm (PAA) wall. Relative (normalized on basis of
-actin levels) basal levels of (A) p65-NF-	B, (B) c-jun protein,
and their activated forms (NF-	B active and p-c-jun) and (C)
CCAAAT/enhancer-binding protein (C/EBP)-, C/EBP-, and
C/EBP-
 in homogenates of AAA (black), PAA (gray), and con-
trol aorta (white). NF-	B and activator protein-1 (AP-1) baseline
and activation levels were comparable in AAA and PAA (pNF	B,
P  .537; pNF-	B active, P  .643; c Jun, P  .877; p-c-Jun,
P  .643). The three isoforms C/EBP-, C/EBP-, and
C/EBP-
 were significantly lower in PAA (C/EBP- and
C/EBP-; P  .005; C/EBP-
, P  .009). A statistical differ-
ence (P  .05) between two groups is indicated by a horizontal
bar above the bars.Fig 2. Concentrations of (A) interleukin (IL)-6 and (B) IL-8
protein are characteristic for abdominal aortic aneurysm (AAA)
and popliteal artery aneurysm (PAA) wall. Aortic wall protein
expression levels of IL-6 and IL-8 were determined by specific
enzyme-linked immunosorbent assays in PAA (gray) and AAA
(black) wall and control aorta (white) samples. There was a strong
significant difference between the control aorta and the aneurysm
group (P  .0001) with respect to IL-6 and IL-8. Focussing on
AAA and PAA, IL-8 hyperexpression was found in the two condi-
tions (P .378) but IL-6 hyperexpression was less obvious in PAA
(P  .038). A statistical difference (P  .05) between two groupsTable III. Aortic wall cytokine protein levels normalized
on basis of protein levels
Variable
PAA, pg/mg AAA, pg/mg P
valueaMedian (IQR) Median (IQR)
IL-1 ND (ND-0.14) 0.14 (ND-0.34) .131
IL-1 1.50 (0.87-2.46) 2.81 (2.00-7.54) .04
IL-13 ND (ND-0.06) 0.18 (0.09-0.28) .001
TNF- ND (ND-0.01) 0.04 (0.01-0.11) .007
Interferon- ND (ND-ND) 1.32 (ND-3.62) .008
IP-10 5.7 (1.3-38.8) 141.2 (63.0-237.0) .0001
MCP-1 67.3 (14.2-127.3) 197.2 (102.1-212.7) .006
MIP-1 1.29 (0.38-1.83) 4.65 (3.52-9.81) .0003
MIP-1 2.77 (0.55-5.71) 20.0 (10.1-26.6) .001
G-CSF ND (ND-0.13) 0.73 (0.40-1.77) .001
AAA, Abdominal aortic aneurysm; G-CSF, granulocyte colony-stimulating
factor; IL, interleukin; IP-10, interferon--induced protein; IQR, interquar-
tile range; MCP-1, monocyte chemotactic protein; MIP-1, macrophage
inflammatory protein-1; ND, not detectable; PAA, popliteal artery aneu-
rysm; TNF, tumor necrosis factor.ing of the aortic wall as well.
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the complexity of the inflammatory and proteolytic cas-
cades in AAA, and the scarcity of data on PAA, we reasoned
that a systematic exploration of common and discordant
inflammatory and proteolytic processes in AAA and PAA
might provide critical clues on the processes that drive
progression of degenerative aneurysms.
An evaluation of the inflammatory and proteolytic fin-
Fig 4. Pro and active forms of matrix metalloprotein
abdominal aortic aneurysm (AAA) and popliteal artery
forms of (A)MMP2, (B)MMP8, (C)MMP9, and (D) c
aorta control (white) tissues. Equal dominance of MMP
the pro and active (act) form (proMMP2, P .217; actM
pro MMP9, P .123; act MMP9, P .280). Results for
than in AAA (pro cathepsin K, P  .021; act cathepsin K
.009; pro cathepsin S, P  .065; act cathepsin S, P  .0
indicated by a horizontal bar above the bars.gerprints in AAA and PAA showed remarkable similaritiesand dissimilarities. Both conditions are characterized by a
strong activation of the general inflammatory transcription
factors NF-	B and AP-1 (c-jun), profuse IL-8 and IL-6
expression, a high neutrophil andmacrophage content, and
abundant expression and activation of the MMP proteases
neutrophil collagenase (MMP8) and gelatinase (MMP9)
and the cysteine proteases cathepsin K, L, and S. Unlike the
congruent findings for IL-6 and IL-8, much lower levels
MMP) and cathepsin proteases are characterized for
ysm (PAA). Western blot analysis of pro and activated
sin K, (E) L and (F) S in AAA (black), PAA (gray), and
P8, and MMP9 were found in AAA and PAA both for
, P .537; proMMP8, P .758; actMMP8, P .537;
athepsins were more variable and less outspoken in PAA
.005; pro cathepsin L, P  .165; act cathepsin L, P 
A statistical difference (P  .05) between two groups isase (
aneur
athep
2, MM
MP2
the c
, P 
21).were found for soluble factors such as interferon-, the
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MCP-1, MIP-1 and MIP-1 in PAA. These latter obser-
vations may indicate that these factors are less critical to
aneurysm growth and particularly challenge a role for in-
terferon- in the progression of AAA.29
Dominance of neutrophil-derived proteases and neu-
trophil abundance in AAA and PAA biopsy specimens
suggests that these cells are generic for these forms of
aneurysmal disease. Neutrophils have long been considered
part of an acute inflammatory response, and their role in
chronic conditions has long been ignored.30 Recent stud-
ies, however, show that neutrophils do participate in
chronic inflammatory processes such as chronic obstructive
pulmonary disease and rosacea.31,32 We previously identi-
fied the neutrophil-derived collagenase MMP8 as the most
prominent MMP protease in AAA and as an important
target for doxycycline therapy in AAA,8,33 suggesting that
neutrophils may also be actively involved in AAA growth.
This notion is supported by animal studies by Eliason et al34
and Pagano et al,35 both of which showed that abrogated
neutrophil influx in an animal models of AAA inhibited
AAA development. Neutrophil abundance in AAA and
PAA can well be explained by the local IL-8 hyperexpres-
sion that is found in the two pathologies. This notion is
supported by observations from a clinical trial that showed
a strong association (r 0.84) between aortic wall neutro-
phil content and IL-8 levels.8
Remarkable differences were found with respect to the
cytotoxic T cell, B cell, and plasma cell content between AAA
(abundant) and PAA (minimal). These differences on the
histologic levels were confirmed by a clear reduction of cell-
type specificmarkers on themRNA level. A clear-cut explana-
tion for this finding is missing, but possible explanations are
the reduced expression of the C/EBP family of transcription
factors in PAA36,37 or, alternatively, that the cytotoxic T-cell,
plasma-cell, and B-cell abundance in AAA reflects presence of
the vascular associated lymphoid tissue38 in this section of
infrarenal aorta.
It is possible that the reduced cytotoxic T-cell content
reflects skewing of the Th1/Th2 balance towards a more
Th1-dominated response, as indicated by similar T-bet but
lower GATA-3 levels in PAA. Yet, the reduced interferon-
and IP-10 levels in the disease do not support such a scenario.
Another possibility is that the differences in the T-helper cell
and cytotoxic T-cell content relates to diverging roles of
specific signaling pathways in CD8T-cell and CD4T-cell
biology.39,40 Minimal B cell and plasma cell infiltration in
PAA challenges a critical role for these cells—and the concept
of AAA as an autoimmune phenomenon—in aneurysm
growth. Yet, little is known about the pathophysiologic role of
these cells in the context of AAA, and further mechanistic
studies are necessary to investigate the contribution of these
cells and the relevance of a possible autoimmune phenome-
non41,42 to AAA formation and progression.
The proteolytic imbalance in AAA with prominent
expression of MMP28,9 and the cysteine proteases cathep-
sin K, L, and S is a key factor of AAA. With the notable
exception of reduced cathepsin K activation and increasedMMP2 in PAA, the inflammatory differences between AAA
and PAA were not followed by a change in MMP or
cysteine protease levels or activation. We have no clear
explanation for the reduced cathepsin K and increased
MMP2 activation in PAA. One possible explanation for the
reduced cathepsin K activation in PAA is that it reflects
reduced expression and/or activity of the osteoclastic pro-
ton pump V-H-adenosine triphosphatase8 that is required
for maintenance of an acidic pericellular microenvironment
that is required for cathepsin K activation and stability.
A possible limitation of this study is that it is based on
assumed parallels in the pathophysiology. Despite the clear
epidemiologic links between AAA and PAA, it is important
to realize that the biologic profiles of the two vessels may
differ; for example, elastic vs muscular artery, different in
flow profiles, complications through rupture (AAA) vs
thrombosis (PAA). Yet, a functional analysis of the popliteal
artery showed that the wall function of the popliteal artery
clearly differs from other peripheral arteries, and instead
shows striking similarities to the abdominal aorta.15 Simi-
larly, although AAA and PAA may differ in their flow
profile, previous work has shown that the flow velocities in
larger vessels prevent adhesion and tissue migration of T
cells and monocytes into the wall and that inflammatory
cells require the vasa vasora in the adventitial rather than the
intimal layer to enter the vessel.43
CONCLUSION
This explorative study demonstrates a remarkable over-
lap between AAA and PAA and characterizes the two
pathologies as general inflammatory conditions dominated
by activation of the NF-	B and AP-1 pathways, IL8 hyper-
expression and neutrophil involvement, as well as ample
activation of selected MMP and cysteine proteases. Re-
markable and consistent differences were found with re-
spect to B cells, plasma cells and cytotoxic T cells and their
markers, suggesting that these cell types are specific for
AAA and are not critical to the process of aneurysmal
growth. Pharmaceutic strategies targeting the generic com-
ponents in AAA and PAA may prove effective for the
stabilization of AAA.10
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